文献速递咽喉与嗓音

喉上神经阻滞在非咳嗽性喉部高反应性中的应用

The Application of Superior Laryngeal Nerve Block for Non-Cough Laryngeal Hypersensitivity.
PubMed 文献 · Laryngoscope · 2023-09-26

该回顾性研究纳入46例常规药物治疗无效的非咳嗽性喉部症状患者,接受喉上神经阻滞。46例中约35例症状平均改善51.0%,疗效平均持续7.60周;痉挛性发声障碍、吞咽痛和舌骨综合征改善率最高(75%-77.5%),癔球感最低(约25%)。5例出现短暂轻微不良反应并自行缓解。作者认为需更大样本进一步研究。

要点

  • 46例中约35例报告症状平均改善51.0%,疗效平均持续7.60周。
  • 痉挛性发声障碍、吞咽痛和舌骨综合征平均改善75%-77.5%,癔球感约25%。
  • 5例注射后即刻出现轻微不良反应,均自行缓解。

核心结论

  • 诊室喉上神经阻滞用于非咳嗽性喉部疾病需更大样本的进一步研究以更好明确其疗效。

研究设计与样本

  • 回顾性病历审查,纳入2019年7月至2022年3月期间因非咳嗽适应症接受喉上神经阻滞的46例患者,收集人口学、合并症和患者报告结局。

主要发现

  • 队列平均接受双侧注射1.24次(范围0-7)和单侧注射0.87次(范围0-4)。
  • 46例中约35例报告症状平均改善51.0%,疗效平均持续7.60周。
  • 亚组分析中痉挛性发声障碍、吞咽痛和舌骨综合征患者平均改善百分比最高(75%-77.5%)。
  • 癔球感患者对该治疗的平均改善百分比最低,仅约25%。
  • 5例在注射后即刻出现轻微不良反应并自行缓解。

关键数值与推荐

  • 主要诊断包括吞咽痛、咽喉痛、颈部痛、肌紧张性发声障碍、癔球感、舌骨综合征和Eagle综合征。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出该应用需更大样本的进一步研究以更好明确疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE(S): To investigate the effect of superior laryngeal nerve (SLN) block in patients with non-cough complaints relating to laryngeal who have failed conventional medical therapy. METHODS: Retrospective chart review of 46 patients who underwent SLN block for non-cough indications between July 2019 and March 2022 was performed. Demographics, comorbidities, and patient-reported outcomes were collected. The primary diagnoses for this group included: odynophagia, throat pain, cervicalgia, muscle tension dysphonia, globus sensation, hyoid bone syndrome, and Eagle syndrome. RESULTS: The cohort underwent an average of 1.24 bilateral injections (range 0-7) and 0.87 unilateral injections (range 0-4). About 35 of 46 patients reported an average of 51.0% improvement in their symptoms, with the treatment effect lasting 7.60 weeks on average. On subgroup analysis, the patients with spasmodic dysphonia, odynophagia, and hyoid bone syndrome had the best percent improvement on average (75%-77.5%). Patients with globus sensation had the lowest percent improvement on average in response to this therapy, reporting only about 25%. Five patients experienced a mild adverse reaction immediately following injection which resolved spontaneously. CONCLUSION: The use of in-office SLN block for non-cough disorders involving the larynx requires further study with larger sample sizes to better delineate the efficacy of these applications. LEVEL OF EVIDENCE: 4 Laryngoscope, 134:1765-1768, 2024.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Benninger MS, Quinton BA, Tierney WS, et al. The Application of Superior Laryngeal Nerve Block for Non-Cough Laryngeal Hypersensitivity. Laryngoscope. 2023. PMID: 37750578. doi:10.1002/lary.31075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。